|
|
Post by JHam on Jun 21, 2017 1:47:23 GMT
This has been on a tear the last couple days. Investors storming back in in anticipation of 3Q data?
|
|
|
|
Post by hansgruber on Jul 14, 2017 13:12:40 GMT
New CFO announced on july 6th seems to have worked for many companies that get bought out for billions. Very interesting. Might increase my position here.
|
|
|
|
Post by bernstein on Jul 26, 2017 12:16:05 GMT
Ladenburg Thalmann raised its price target on Axsome Therapeutics (NASDAQ: AXSM) to $31.00 (from $28.00) while maintaining a Buy rating. July 26, 2017 6:48 AM EDT www.streetinsider.com/Analyst+Comments/Axsome+Therapeutics+(AXSM)+PT+Raised+to+%2431+at+Ladenburg+Thalmann/13129605.htmlAnalyst Matt Kaplan comments "Interim Phase 3 data for CRPS is expected in 4Q17, with AXS-02 potentially being initially launched in the US in 2019, and other indications following in later years. We estimate AXS-02 can achieve $150 million in revenue in CRPS, with other pain indications also adding materially. At peak, we estimate AXS-02 can reach $600 million." |
|
|
|
Post by bernstein on Dec 20, 2017 17:50:53 GMT
2 BIG P3 READOUT THIS MONTH=$$$$$ GET SOME AXSM AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH = Could run to $20+ .Sabby Management just bought 1.4 Million shares a few days ago which is a good sign .GL Axsome Therapeutics (AXSM) Market Cap: $120 M Cash $40 M Price: $4.75 Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions) Presentation from mid November (see slide 36 for upcoming milestones) media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_13%20Nov%202017.pdfAnticipated Near-Term Clinical Milestones
• Clinical Trial Readouts:
Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018)
Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018)
Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018)Axsome Therapeutics Inc (AXSM) Stake Owned by Sabby Management, LLC...Dec 4th, 2017 www.themarketsdaily.com/2017/12/04/axsome-therapeutics-inc-axsm-stake-owned-by-sabby-management-llc.html |
|
|
|
Post by JHam on Jan 9, 2018 16:23:09 GMT
|
|
|
|
Post by omstem on May 15, 2019 2:08:24 GMT
Rebound to $5+ coming ,stock is heavily oversold and massive undervalued thanks to the small shareoffering which created this fantastic entry opp .  |
|
|
|
Post by omstem on May 15, 2019 2:12:45 GMT
Bernstein:
Thanks for suggesting this stock.
I started a small pilot position after I read your initial post and my own DD. I added just a few hundred shares on the dips. I wish I kept the additional shares I added on top of my pilot position. I sold them for tax losses but held on to my pilot position.
Today the stock is looking really good. Sold portion of my pilot position to get back my initial investment. Now I am letting the house money ride.
Thanks again for recommending this stock.
|
|
|
|
Post by JHam on May 15, 2019 4:46:44 GMT
Bernstein: Thanks for suggesting this stock. I started a small pilot position after I read your initial post and my own DD. I added just a few hundred shares on the dips. I wish I kept the additional shares I added on top of my pilot position. I sold them for tax losses but held on to my pilot position. Today the stock is looking really good. Sold portion of my pilot position to get back my initial investment. Now I am letting the house money ride. Thanks again for recommending this stock. Wow, nicely done. Congrats! |
|
